Cargando…
RANKL and OPG Polymorphisms Are Associated with Aromatase Inhibitor-Related Musculoskeletal Adverse Events in Chinese Han Breast Cancer Patients
BACKGROUND: Breast cancer patients treated with aromatase inhibitors (AIs) may experience musculoskeletal adverse events (MS-AEs). Several studies have confirmed that the RANKL/RANK/OPG signaling pathway plays a dominant role in bone health. Therefore, this study aimed to analyze the relationship be...
Autores principales: | Wang, Jingxuan, Lu, Kangping, Song, Ying, Zhao, Shu, Ma, Wenjie, Xuan, Qijia, Tang, Dabei, Zhao, Hong, Liu, Lei, Zhang, Qingyuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4547828/ https://www.ncbi.nlm.nih.gov/pubmed/26218592 http://dx.doi.org/10.1371/journal.pone.0133964 |
Ejemplares similares
-
Indications of Clinical and Genetic Predictors for Aromatase Inhibitors Related Musculoskeletal Adverse Events in Chinese Han Women with Breast Cancer
por: Wang, Jingxuan, et al.
Publicado: (2013) -
Attempted replication of SNPs in RANKL and OPG with musculoskeletal adverse events during aromatase inhibitor treatment for breast cancer
por: Dempsey, Jacqueline M., et al.
Publicado: (2018) -
Serum RANKL, osteoprotegerin (OPG), and RANKL/OPG ratio in nephrotic children
por: Wasilewska, Anna, et al.
Publicado: (2010) -
Musculoskeletal Adverse Events Associated with Adjuvant Aromatase Inhibitors
por: Khan, Qamar J., et al.
Publicado: (2010) -
Association of RANKL and OPG Gene Polymorphism in Arab Women with and without Osteoporosis
por: Abdi, Saba, et al.
Publicado: (2021)